|
مقاله
|
Abstract
|
|
|
|
Title:
|
Intravitreal Bevasizumab Injection versus Eylea Injection for Treatment of Retinopathy of Prematurity, Two Years Study Results.
|
|
Author(s):
|
Gholamali Naderian, Valleh Sajjadi, Mohammad Ashkan Naderian
|
|
Presentation Type:
|
Poster
|
|
Subject:
|
Retina and Retinal Cell Biology
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Gholamali Naderian
|
|
Affiliation :(optional)
|
|
|
E mail:
|
sana.gv@gmail.com
|
|
Phone:
|
03136271015
|
|
Mobile:
|
09131136346
|
|
|
|
|
Purpose:
|
To compare the outcomes of injection Eylea versus IVB in premature infants diagnosed with ROP
|
|
Methods:
|
Patients who were diagnosed with ROP in Esfahan ROP Center and needed intravitreal injection for disease control were included. The outcomes were stratified and analyzed, based on the treatment type and ROP zone.
|
|
Results:
|
From 76 patients who diagnosed with ROP progression during two years of investigation, 55 eyes (36%) were treated with Eylea injection and 84 eyes (55%) were treated with IVB injection while 13 eyes (9%) did not showed ROP. The eyes for injection selected randomly. After injection patients went on antibiotics and corticosteroids for 5 days. They were visited one and seven and 14 days after injection. ROP progression in all patients was eliminated with injection and none of them needed LASER therapy.
|
|
Conclusion:
|
The investigation of short time outcomes showed no significant difference either in complications or eliminating disease between two drugs. Long term outcomes are under study.
|
|
Attachment:
|
67article2.pptx
|
|